Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-chain (AL) AmyloidosisGlobeNewsWire • 06/22/21
Genmab and Bolt Biotherapeutics Announce Oncology Research and Development CollaborationGlobeNewsWire • 06/02/21
Genmab to Participate in a Virtual Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare ConferenceGlobeNewsWire • 06/01/21
Genmab - Janssen's Darzalex Wins Positive Opinion In Europe For Two New IndicationsBenzinga • 05/21/21
Genmab Announces that Janssen has been Granted U.S. FDA Approval for RYBREVANT™ (amivantamab-vmjw) for Patients with Metastatic Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion MutationsGlobeNewsWire • 05/21/21
Genmab Announces that Janssen has Received Positive CHMP Opinion Recommending DARZALEX® (daratumumab) Subcutaneous (SC) Formulation for Patients with Newly Diagnosed Light-chain (AL) AmyloidosisGlobeNewsWire • 05/21/21
Genmab Announces Abstracts Evaluating Products in Pipeline, Portfolio to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) CongressGlobeNewsWire • 05/19/21
Genmab A/S (GMAB) CEO Jan van de Winkel on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/05/21
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2021GlobeNewsWire • 04/20/21
Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees and a New Member of Management in GenmabGlobeNewsWire • 04/13/21
Seagen and Genmab Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical CancerBusiness Wire • 04/09/21
Genmab Announces European Marketing Authorization for Kesimpta® (ofatumumab) in Relapsing Multiple SclerosisGlobeNewsWire • 03/30/21
Genmab Announces Preclinical Data to be Presented at American Association for Cancer Research (AACR) Annual Meeting 2021GlobeNewsWire • 03/10/21
Genmab A/S (GMAB) CEO Jan van de Winkel on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/23/21
Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental MedicinesGlobeNewsWire • 02/22/21
The $12 Billion Market That Has Biotech Stocks Hijacking The Immune SystemInvestors Business Daily • 02/12/21
Genmab, Seagen File US Application For Tisotumab Vedotin In Cervical Cancer SettingBenzinga • 02/11/21
Seagen and Genmab Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical CancerBusiness Wire • 02/10/21
Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical CancerGlobeNewsWire • 02/10/21
